Ads
related to: immunometabolic rewiring for kidney disease life expectancy
Search results
Results From The WOW.Com Content Network
MeSH. D017582. [edit on Wikidata] Renal replacement therapy (RRT) is therapy that replaces the normal blood -filtering function of the kidneys. It is used when the kidneys are not working well, which is called kidney failure and includes acute kidney injury and chronic kidney disease. Renal replacement therapy includes dialysis (hemodialysis or ...
Bortezomib-based management, Organ transplant. Monoclonal immunoglobulin deposition disease, or MIDD, is a disease characterised by the deposition of monoclonal immunoglobulins on the basement membrane of the kidney. Monoclonal immunoglobulins are produced by monoclonal plasma cells, which are found in a variety of plasma cell dyscrasias.
1.2 million (2015) [ 6 ] Chronic kidney disease (CKD) is a type of long-term kidney disease, in which either there is a gradual loss of kidney function occurs over a period of months to years, or abnormal kidney structure (with normal function). [ 2 ][ 5 ] Initially generally no symptoms are seen, but later symptoms may include leg swelling ...
aHUS. Specialty. Hematology. Atypical hemolytic uremic syndrome (aHUS), also known as complement-mediated hemolytic uremic syndrome, not to be confused with Hemolytic–uremic syndrome is an extremely rare, life-threatening, progressive disease that frequently has a genetic component. In most cases it can be effectively controlled by ...
Autosomal dominant polycystic kidney disease (ADPKD) is the most common of all the inherited cystic kidney diseases [12] [13] [14] with an incidence of 1:500 live births. [12] [14] Studies show that 10% of end-stage kidney disease (ESKD) patients being treated with dialysis in Europe and the U.S. were initially diagnosed and treated for ADPKD ...
Barakat syndrome is a rare disease characterized by hypoparathyroidism, sensorineural deafness and renal disease, and hence also known as HDR syndrome. It is an autosomal dominant condition with incomplete penetrance and variable expressivity [2] that was first described by Amin J. Barakat et al. in 1977. [3]
Ads
related to: immunometabolic rewiring for kidney disease life expectancy